Testing lunsekimig for COPD with frequent flare-ups
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have had COPD for at least one year
- You smoke or used to smoke (at least 10 pack-years, e.g., 1 pack a day for 10 years)
- You have had at least 2 moderate or 1 severe COPD flare-up in the past year
- You are currently on triple therapy (three different inhalers) for at least 12 weeks
- Your blood eosinophil count is at least 150, and your body mass index is between 18 and 40
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study is a long-term follow-up for people with COPD who have already completed an earlier lunsekimig study. It aims to check the safety and effectiveness of the treatment over a longer period.
This trial tests a new medicine called CM512 (given as an injection) to see if it can reduce COPD flare-ups and improve lung function. It is for people with moderate-to-severe COPD who have had recent flare-ups despite using inhalers.
This trial tests if inhaled corticosteroids (ICS) work better for COPD patients with different eosinophil levels. You must already be taking two long-acting bronchodilators and have stopped smoking for at least 6 months.
This study tests a new medication called CM310 for people with moderate to severe COPD who have frequent flare-ups and a certain type of inflammation. The goal is to see if CM310 can reduce these flare-ups and improve breathing.
This trial tests the long-term safety and effectiveness of Lunsekimig, an investigational drug, for adults with asthma. It is for people who have already completed a previous Lunsekimig study and are on stable asthma medications.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.